(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are Liberty TripAdvisor Holdings, Advanced Semiconductor Engineering, and Novo Nordisk A/S.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Liberty TripAdvisor Holdings (LTRPA) | 1.61 | 17.52% | 2024-03-07 03:07:07 |
| 2 | Advanced Semiconductor Engineering (ASX) | 11.65 | 9.8% | 2024-03-07 14:52:38 |
| 3 | Novo Nordisk A/S (NVO) | 135.86 | 8.9% | 2024-03-07 15:21:45 |
| 4 | Pacific Biosciences of California (PACB) | 4.54 | 8.85% | 2024-03-07 15:14:16 |
| 5 | Exact Sciences (EXAS) | 60.99 | 8.38% | 2024-03-07 15:12:05 |
| 6 | Ringcentral (RNG) | 34.95 | 8.24% | 2024-03-07 15:58:36 |
| 7 | Burlington Stores (BURL) | 222.74 | 8.2% | 2024-03-07 15:19:00 |
| 8 | Maiden Holdings, Ltd. (MHLD) | 1.38 | 7.81% | 2024-03-07 07:12:06 |
| 9 | MediWound Ltd. (MDWD) | 16.58 | 7.52% | 2024-03-07 05:10:06 |
| 10 | Mannatech (MTEX) | 8.86 | 7.38% | 2024-03-07 10:41:07 |
The three biggest losers today are Viking Therapeutics, American Public Education, and LivePerson.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Viking Therapeutics (VKTX) | 74.60 | -18.19% | 2024-03-07 15:17:52 |
| 2 | American Public Education (APEI) | 13.53 | -13.12% | 2024-03-07 15:10:47 |
| 3 | LivePerson (LPSN) | 1.01 | -10.62% | 2024-03-07 01:42:06 |
| 4 | Inovio Pharmaceuticals (INO) | 8.97 | -9.12% | 2024-03-07 15:13:13 |
| 5 | FuelCell Energy (FCEL) | 1.12 | -8.2% | 2024-03-07 15:12:16 |
| 6 | MEI Pharma (MEIP) | 3.69 | -7.29% | 2024-03-07 05:13:06 |
| 7 | FibroGen (FGEN) | 1.75 | -6.68% | 2024-03-07 13:12:16 |
| 8 | TherapeuticsMD (TXMD) | 2.30 | -6.12% | 2024-03-07 15:17:44 |
| 9 | Kamada Ltd. (KMDA) | 6.05 | -6.06% | 2024-03-06 21:11:06 |
| 10 | Netlist (NLST) | 1.57 | -4.85% | 2024-03-07 13:09:06 |
Winners today
1. Liberty TripAdvisor Holdings (LTRPA) – 17.52%
Liberty TripAdvisor Holdings, Inc., through its subsidiaries, operates a travel guidance platform that connects people and audience with travel partners. The company operates through three segments: Tripadvisor Core, Viator, and TheFork. It offers an online platform that provides content, travel guidance products and services, and two-sided marketplaces for travelers to discover, generate, and share authentic user-generated content in the form of ratings and reviews for destinations, points-of-interest, experiences, accommodations, restaurants, cruises, and other travel categories, including alternative accommodations, flights, and rental cars in approximately 40 countries and 20 languages worldwide. The company also provides click-based, display-based, and subscription-based advertising services. In addition, it operates Viator, an online marketplace that includes website, mobile web, and mobile app, which allows travelers to research and book tours, activities, and attractions in travel destinations worldwide; and TheFork, an online restaurant reservations platform that offers information and services for consumers to research and book restaurants. The company was incorporated in 2013 and is headquartered in Englewood, Colorado.
NASDAQ ended the session with Liberty TripAdvisor Holdings jumping 17.52% to $1.61 on Thursday while NASDAQ rose 1.51% to $16,273.38.
Earnings Per Share
As for profitability, Liberty TripAdvisor Holdings has a trailing twelve months EPS of $-3.75.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -58.39%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.2%, now sitting on 1.79B for the twelve trailing months.
Yearly Top and Bottom Value
Liberty TripAdvisor Holdings’s stock is valued at $1.61 at 16:32 EST, under its 52-week high of $1.73 and way higher than its 52-week low of $0.15.
More news about Liberty TripAdvisor Holdings.
2. Advanced Semiconductor Engineering (ASX) – 9.8%
ASE Technology Holding Co., Ltd., together with its subsidiaries, provides semiconductors packaging and testing, and electronic manufacturing services in the United States, Taiwan, Asia, Europe, and internationally. It develops, constructs, sells, leases, and manages real estate properties; produces substrates; offers information software, equipment leasing, investment advisory, and warehousing management services; processes and sells computer and communication peripherals, electronic components, telecommunications equipment, and motherboards; and imports and exports goods and technology. ASE Technology Holding Co., Ltd. was founded in 1984 and is headquartered in Kaohsiung, Taiwan.
NYSE ended the session with Advanced Semiconductor Engineering rising 9.8% to $11.65 on Thursday, after five consecutive sessions in a row of gains. NYSE rose 0.71% to $17,927.98, following the last session’s upward trend on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, Advanced Semiconductor Engineering has a trailing twelve months EPS of $0.46.
PE Ratio
Advanced Semiconductor Engineering has a trailing twelve months price to earnings ratio of 25.33. Meaning, the purchaser of the share is investing $25.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.52%.
Volume
Today’s last reported volume for Advanced Semiconductor Engineering is 6320440 which is 11.29% above its average volume of 5678900.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 30, 2023, the estimated forward annual dividend rate is 0.57 and the estimated forward annual dividend yield is 5.77%.
Volatility
Advanced Semiconductor Engineering’s last week, last month’s, and last quarter’s current intraday variation average was 1.15%, 0.47%, and 1.47%.
Advanced Semiconductor Engineering’s highest amplitude of average volatility was 1.15% (last week), 1.47% (last month), and 1.47% (last quarter).
More news about Advanced Semiconductor Engineering.
3. Novo Nordisk A/S (NVO) – 8.9%
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
NYSE ended the session with Novo Nordisk A/S rising 8.9% to $135.86 on Thursday, after two consecutive sessions in a row of gains. NYSE rose 0.71% to $17,927.98, following the last session’s upward trend on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, Novo Nordisk A/S has a trailing twelve months EPS of $2.71.
PE Ratio
Novo Nordisk A/S has a trailing twelve months price to earnings ratio of 50.13. Meaning, the purchaser of the share is investing $50.13 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 88.07%.
Moving Average
Novo Nordisk A/S’s worth is way above its 50-day moving average of $112.02 and way above its 200-day moving average of $95.68.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Novo Nordisk A/S’s EBITDA is 2.37.
More news about Novo Nordisk A/S.
4. Pacific Biosciences of California (PACB) – 8.85%
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
NASDAQ ended the session with Pacific Biosciences of California rising 8.85% to $4.54 on Thursday while NASDAQ rose 1.51% to $16,273.38.
Earnings Per Share
As for profitability, Pacific Biosciences of California has a trailing twelve months EPS of $-1.21.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -48.53%.
Volume
Today’s last reported volume for Pacific Biosciences of California is 11810100 which is 42.15% above its average volume of 8307890.
Yearly Top and Bottom Value
Pacific Biosciences of California’s stock is valued at $4.54 at 16:32 EST, under its 52-week low of $4.97.
More news about Pacific Biosciences of California.
5. Exact Sciences (EXAS) – 8.38%
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
NASDAQ ended the session with Exact Sciences rising 8.38% to $60.99 on Thursday while NASDAQ rose 1.51% to $16,273.38.
Earnings Per Share
As for profitability, Exact Sciences has a trailing twelve months EPS of $-1.13.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.6%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 11.9% and positive 51.1% for the next.
Moving Average
Exact Sciences’s worth is under its 50-day moving average of $65.49 and way under its 200-day moving average of $74.87.
Volume
Today’s last reported volume for Exact Sciences is 1443210 which is 26.99% below its average volume of 1976840.
More news about Exact Sciences.
6. Ringcentral (RNG) – 8.24%
RingCentral, Inc., together with its subsidiaries, provides cloud communications, video meetings, collaboration, and contact center software-as-a-service solutions worldwide. The company's products include RingCentral Message Video Phone that provides a unified experience for communication and collaboration across multiple modes, including HD voice, video, SMS, messaging and collaboration, conferencing, online meetings, and fax; RingCentral Contact Center, a collaborative contact center solution that delivers AI-powered omnichannel and workforce engagement solutions with integrated RingCentral MVP; and RingCX, an AI-powered contact center that a native delivers omnichannel experience. It provides RingCentral Video, a video meeting service that includes the company's RCV video and team messaging capabilities; offers video and audio conferencing, team messaging, file sharing, contact, task, and calendar management, as well as pre-meeting, in-meeting, and post-meeting capabilities. In addition, the company offers RingCentral Professional Services, which include consultation, UCaaS and CCaaS implementation, VoIP phone system adoption, configuring custom workflows, customer and user onboarding, ongoing support, advanced support, managed services, and more. It serves a range of industries, including financial services, education, healthcare, legal services, real estate, retail, technology, insurance, construction, hospitality, state and local government, and others. It sells its products to enterprise customers, as well as small and medium-sized businesses through resellers and distributors, partners, and global service providers. RingCentral, Inc. was incorporated in 1999 and is headquartered in Belmont, California.
NYSE ended the session with Ringcentral jumping 8.24% to $34.95 on Thursday, after two successive sessions in a row of gains. NYSE jumped 0.71% to $17,927.98, following the last session’s upward trend on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, Ringcentral has a trailing twelve months EPS of $-1.74.
More news about Ringcentral.
7. Burlington Stores (BURL) – 8.2%
Burlington Stores, Inc. operates as a retailer of branded apparel products in the United States. The company provides fashion-focused merchandise, including women's ready-to-wear apparel, menswear, youth apparel, footwear, accessories, toys, gifts, and coats, as well as baby, home, and beauty products. It operates stores under the Burlington Stores, and Cohoes Fashions brand names in Puerto Rico. Burlington Stores, Inc. was founded in 1972 and is headquartered in Burlington, New Jersey.
NYSE ended the session with Burlington Stores jumping 8.2% to $222.74 on Thursday while NYSE jumped 0.71% to $17,927.98.
Burlington stores (burl) tops Q4 earnings and revenue estimatesWhile Burlington Stores has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?
Here's what key metrics tell us about burlington stores (burl) Q4 earningsFor the quarter ended January 2024, Burlington Stores (BURL Quick QuoteBURL – Free Report) reported revenue of $3.13 billion, up 13.9% over the same period last year. , Here is how Burlington Stores performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Earnings Per Share
As for profitability, Burlington Stores has a trailing twelve months EPS of $4.55.
PE Ratio
Burlington Stores has a trailing twelve months price to earnings ratio of 48.95. Meaning, the purchaser of the share is investing $48.95 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 39.94%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Burlington Stores’s EBITDA is 72.86.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 9.5% and 29.8%, respectively.
More news about Burlington Stores.
8. Maiden Holdings, Ltd. (MHLD) – 7.81%
Maiden Holdings, Ltd., through its subsidiaries, provides property and casualty reinsurance solutions to regional and specialty insurers in Europe, the United States, and internationally. It operates in two segments: Diversified Reinsurance and AmTrust Reinsurance. The company writes treaties on a quota share basis and excess of loss basis. It also offers auto and credit life insurance products through its insurer partners to retail clients; and a range of legacy services to small insurance companies. The company was founded in 2007 and is headquartered in Pembroke, Bermuda.
NASDAQ ended the session with Maiden Holdings, Ltd. jumping 7.81% to $1.38 on Thursday, following the last session’s upward trend. NASDAQ rose 1.51% to $16,273.38, following the last session’s upward trend on what was an all-around up trend trading session today.
Earnings Per Share
As for profitability, Maiden Holdings, Ltd. has a trailing twelve months EPS of $0.23.
PE Ratio
Maiden Holdings, Ltd. has a trailing twelve months price to earnings ratio of 6. Meaning, the purchaser of the share is investing $6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -23.29%.
More news about Maiden Holdings, Ltd..
9. MediWound Ltd. (MDWD) – 7.52%
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
NASDAQ ended the session with MediWound Ltd. rising 7.52% to $16.58 on Thursday, after three successive sessions in a row of gains. NASDAQ rose 1.51% to $16,273.38, following the last session’s upward trend on what was an all-around positive trend trading session today.
Earnings Per Share
As for profitability, MediWound Ltd. has a trailing twelve months EPS of $-1.82.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -71.63%.
More news about MediWound Ltd..
10. Mannatech (MTEX) – 7.38%
Mannatech, Incorporated operates as a health and wellness company worldwide. It develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management products. The company primarily sells its products directly, as well as through network marketing channels and a website. Mannatech, Incorporated was founded in 1993 and is headquartered in Flower Mound, Texas.
NASDAQ ended the session with Mannatech rising 7.38% to $8.86 on Thursday, after two consecutive sessions in a row of gains. NASDAQ jumped 1.51% to $16,273.38, following the last session’s upward trend on what was an all-around positive trend exchanging session today.
Earnings Per Share
As for profitability, Mannatech has a trailing twelve months EPS of $-3.66.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -47.71%.
Moving Average
Mannatech’s worth is above its 50-day moving average of $8.82 and way below its 200-day moving average of $10.49.
More news about Mannatech.
Losers Today
1. Viking Therapeutics (VKTX) – -18.19%
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
NASDAQ ended the session with Viking Therapeutics falling 18.19% to $74.60 on Thursday while NASDAQ jumped 1.51% to $16,273.38.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.91.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.79%.
Volatility
Viking Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was 4.62%, 2.96%, and 4.21%.
Viking Therapeutics’s highest amplitude of average volatility was 7.23% (last week), 7.00% (last month), and 4.21% (last quarter).
Volume
Today’s last reported volume for Viking Therapeutics is 15476600 which is 183.77% above its average volume of 5453810.
More news about Viking Therapeutics.
2. American Public Education (APEI) – -13.12%
American Public Education, Inc., together with its subsidiaries, provides online and campus-based postsecondary education and career learning. It operates through three segments: American Public University System, Rasmussen University, and Hondros College of Nursing. The company offers 136 degree programs and 115 certificate programs in various fields of study, including nursing, public health, public administration, and business administration. It also provides nursing-and health sciences-focused postsecondary education, diploma in practical nursing, and an associate degree in nursing. The company was incorporated in 1991 and is headquartered in Charles Town, West Virginia.
NASDAQ ended the session with American Public Education sliding 13.12% to $13.53 on Thursday while NASDAQ jumped 1.51% to $16,273.38.
Earnings Per Share
As for profitability, American Public Education has a trailing twelve months EPS of $-2.94.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.4%.
Previous days news about American Public Education
- Here's what key metrics tell us about american public education (apei) Q4 earnings. According to Zacks on Tuesday, 5 March, "Here is how American Public Education performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
More news about American Public Education.
3. LivePerson (LPSN) – -10.62%
LivePerson, Inc. engages in conversational artificial intelligence. It operates in two segments, Business and Consumer. The Business segment enables brands to leverage the Conversational Cloud's intelligence engine to connect with consumers through an integrated suite of mobile and online business messaging technologies. The Consumer segment facilitates online transactions between experts and users seeking information and knowledge through mobile and online messaging. The company offers the Conversational Cloud, an enterprise-class cloud-based platform, which enables businesses and consumers to connect through conversational interfaces, such as in-app and mobile messaging. It also provides professional services; Tenfold, a customer experience integration platform; VoiceBase, a voice analytics platform for the enterprise; and online marketplace that connects experts who provide information and knowledge through mobile and online messaging with users. The company sells its products through direct and indirect sales channels to Fortune 500 companies, Internet businesses, online merchants, small business sector, automotive dealers, universities, libraries, government agencies, and not-for-profit organizations. It operates in the United States, Canada, Latin America, South America, Europe, the Middle East, Africa, and the Asia-Pacific. LivePerson, Inc. was incorporated in 1995 and is headquartered in New York, New York.
NASDAQ ended the session with LivePerson sliding 10.62% to $1.01 on Thursday while NASDAQ rose 1.51% to $16,273.38.
Earnings Per Share
As for profitability, LivePerson has a trailing twelve months EPS of $-1.28.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -172.83%.
Sales Growth
LivePerson’s sales growth is negative 22.5% for the present quarter and negative 16.9% for the next.
Volume
Today’s last reported volume for LivePerson is 5868920 which is 201.52% above its average volume of 1946390.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 34.8% and a negative 266.7%, respectively.
Moving Average
LivePerson’s value is way under its 50-day moving average of $2.87 and way under its 200-day moving average of $3.56.
More news about LivePerson.
4. Inovio Pharmaceuticals (INO) – -9.12%
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
NASDAQ ended the session with Inovio Pharmaceuticals sliding 9.12% to $8.97 on Thursday while NASDAQ rose 1.51% to $16,273.38.
Earnings Per Share
As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-7.56.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -81.3%.
More news about Inovio Pharmaceuticals.
5. FuelCell Energy (FCEL) – -8.2%
FuelCell Energy, Inc., together with its subsidiaries, manufactures and sells stationary fuel cell and electrolysis platforms that decarbonize power and produce hydrogen. The company provides various configurations and applications of its platform, including on-site power, utility grid support, and microgrid, as well as distributed hydrogen; solid oxide-based electrolysis; solutions for long duration hydrogen-based energy storage and electrolysis technology; and carbon capture, separation, and utilization systems. It also offers technology to produce electricity, heat, hydrogen, and water. In addition, the company provides turn-key solutions, including development, engineering, procurement, construction, interconnection, and operation services. It serves various markets, including utilities and independent power producers, industrial and process applications, education and health care, data centers and communication, wastewater treatment, government, commercial and hospitality, microgrids, manufacturing, industrial hydrogen, port, oil and gas, wind and solar projects, food and beverage, hydrogen for mobility and material handling, and hydrogen fuel for heat, as well as engineering, procurement, and construction firms. The company primarily operates in the United States, South Korea, and Europe. FuelCell Energy, Inc. was founded in 1969 and is headquartered in Danbury, Connecticut.
NASDAQ ended the session with FuelCell Energy sliding 8.2% to $1.12 on Thursday, following the last session’s upward trend. NASDAQ rose 1.51% to $16,273.38, following the last session’s upward trend on what was an all-around positive trend exchanging session today.
Fuelcell energy (fcel) reports Q1 earnings: what key metrics have to sayHere is how FuelCell Energy performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Earnings Per Share
As for profitability, FuelCell Energy has a trailing twelve months EPS of $-0.26.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -14.27%.
Moving Average
FuelCell Energy’s value is way under its 50-day moving average of $1.35 and way below its 200-day moving average of $1.65.
Earnings Before Interest, Taxes, Depreciation, and Amortization
FuelCell Energy’s EBITDA is -14.63.
Volume
Today’s last reported volume for FuelCell Energy is 20587000 which is 49.13% above its average volume of 13803900.
Yearly Top and Bottom Value
FuelCell Energy’s stock is valued at $1.12 at 16:32 EST, way under its 52-week high of $4.02 and way higher than its 52-week low of $0.98.
More news about FuelCell Energy.
6. MEI Pharma (MEIP) – -7.29%
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.
NASDAQ ended the session with MEI Pharma dropping 7.29% to $3.69 on Thursday, after three successive sessions in a row of losses. NASDAQ jumped 1.51% to $16,273.38, following the last session’s upward trend on what was an all-around up trend exchanging session today.
Earnings Per Share
As for profitability, MEI Pharma has a trailing twelve months EPS of $2.98.
PE Ratio
MEI Pharma has a trailing twelve months price to earnings ratio of 1.24. Meaning, the purchaser of the share is investing $1.24 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 36.79%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 34.5% and a drop 5.3% for the next.
Moving Average
MEI Pharma’s value is way under its 50-day moving average of $4.95 and way below its 200-day moving average of $6.29.
More news about MEI Pharma.
7. FibroGen (FGEN) – -6.68%
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
NASDAQ ended the session with FibroGen dropping 6.68% to $1.75 on Thursday while NASDAQ jumped 1.51% to $16,273.38.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-2.92.
Earnings Before Interest, Taxes, Depreciation, and Amortization
FibroGen’s EBITDA is 1.67.
Volatility
FibroGen’s last week, last month’s, and last quarter’s current intraday variation average was a positive 4.21%, a negative 0.82%, and a positive 8.48%.
FibroGen’s highest amplitude of average volatility was 5.94% (last week), 8.77% (last month), and 8.48% (last quarter).
Volume
Today’s last reported volume for FibroGen is 717676 which is 73.74% below its average volume of 2733100.
Yearly Top and Bottom Value
FibroGen’s stock is valued at $1.75 at 16:32 EST, way below its 52-week high of $23.53 and way above its 52-week low of $0.33.
More news about FibroGen.
8. TherapeuticsMD (TXMD) – -6.12%
TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
NASDAQ ended the session with TherapeuticsMD falling 6.12% to $2.30 on Thursday while NASDAQ jumped 1.51% to $16,273.38.
Earnings Per Share
As for profitability, TherapeuticsMD has a trailing twelve months EPS of $4.85.
PE Ratio
TherapeuticsMD has a trailing twelve months price to earnings ratio of 0.47. Meaning, the purchaser of the share is investing $0.47 for every dollar of annual earnings.
Yearly Top and Bottom Value
TherapeuticsMD’s stock is valued at $2.30 at 16:32 EST, way below its 52-week high of $4.99 and way higher than its 52-week low of $1.95.
Moving Average
TherapeuticsMD’s worth is under its 50-day moving average of $2.31 and way under its 200-day moving average of $3.09.
Sales Growth
TherapeuticsMD’s sales growth is negative 97.6% for the ongoing quarter and negative 47.9% for the next.
Volatility
TherapeuticsMD’s last week, last month’s, and last quarter’s current intraday variation average was 3.82%, 1.07%, and 2.03%.
TherapeuticsMD’s highest amplitude of average volatility was 3.82% (last week), 1.74% (last month), and 2.03% (last quarter).
More news about TherapeuticsMD.
9. Kamada Ltd. (KMDA) – -6.06%
Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.
NASDAQ ended the session with Kamada Ltd. dropping 6.06% to $6.05 on Thursday, after two consecutive sessions in a row of losses. NASDAQ rose 1.51% to $16,273.38, following the last session’s upward trend on what was an all-around positive trend trading session today.
Earnings Per Share
As for profitability, Kamada Ltd. has a trailing twelve months EPS of $0.13.
PE Ratio
Kamada Ltd. has a trailing twelve months price to earnings ratio of 46.54. Meaning, the purchaser of the share is investing $46.54 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 17.7%, now sitting on 151.53M for the twelve trailing months.
Volume
Today’s last reported volume for Kamada Ltd. is 113220 which is 315.94% above its average volume of 27220.
Sales Growth
Kamada Ltd.’s sales growth for the current quarter is negative 17%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Kamada Ltd.’s EBITDA is 44.52.
More news about Kamada Ltd..
10. Netlist (NLST) – -4.85%
Netlist, Inc. designs, manufactures, and sells modular memory subsystems for the server, high-performance computing, and communications markets worldwide. It offers HybriDIMM, a storage class memory product, which unifies dynamic random access memory (DRAM) and NAND flash in a plug-and-play module delivering terabyte storage capacities operating at nanosecond memory speeds. The company also provides nonvolatile (NV) memory products, such as NVvault DDR4 NVDIMM that provides data acceleration and protection in a joint electron device engineering council standard DDR4 interface; and specialty DIMMs and embedded flash products for use in data center and industrial applications. It resells solid state drive (SSD), NAND flash, DRAM products, and other component products to storage customers, appliance customers, system builders, and cloud and datacenter customers; and sells component inventory to distributors and other users of memory integrated circuits. The company markets and sells its products primarily to original equipment manufacturers through a direct sales force and a network of independent sales representatives. Netlist, Inc. was incorporated in 2000 and is headquartered in Irvine, California.
NASDAQ ended the session with Netlist sliding 4.85% to $1.57 on Thursday while NASDAQ rose 1.51% to $16,273.38.
Earnings Per Share
As for profitability, Netlist has a trailing twelve months EPS of $-0.25.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -236.88%.
More news about Netlist.
Stay up to date with our winners and losers daily report
